In a $30 billion psoriasis market dominated by multi-billion-dollar incumbents, Oruka Therapeutics is betting that the next biotech frontier isn't discovering novel targets, but re-engineering established ones to stretch injection schedules down to once or twice a year. Built on a repeatable venture platform designed to rapidly package and monetize validated antibodies, the company has leveraged striking early skin-clearance data and disciplined capital raises to accumulate a $1 billion war chest. Yet as Oruka prepares for late-stage trials, it faces a defining strategic tension: can a lean, capital-efficient engineering play outmaneuver entrenched pharmaceutical giants and newly approved oral therapies, or does its soaring valuation reflect an extraordinarily efficient financial structure running ahead of long-term commercial reality?
Podden och tillhörande omslagsbild på den här sidan tillhör
Empor.top. Innehållet i podden är skapat av Empor.top och inte av,
eller tillsammans med, Poddtoppen.
